Background: Machado-Joseph disease (MJD) is an autosomal dominant spinocerebellar ataxia caused by a CAG tract expansions in the ATXN3 gene. Patterns of mitochondrial damage associated with pathological findings of brain tissues could provide molecular biomarkers of this disorder. Objective: The potential of mitochondrial DNA (mtDNA) damage as a biomarker of MJD progression was investigated using a transgenic mouse model. Methods: DNA was obtained from affected (pontine nuclei) and nonaffected tissues (hippocampus and blood) of transgenic animals of three distinct age groups: 8 weeks, before onset of the phenotype; 16 weeks, at onset, and 24 weeks, at well-established phenotype. Wild-type littermate mice, serving as controls, were analyzed for the same tissues and age groups. mtDNA damage was studied by fluorescence-based quantitative PCR in 84 transgenic and 93 wild-type samples. Results: A clear pattern of decrease in mtDNA copy number with age and accumulation of 3,867-bp deletions at the initial stages (both being more pronounced in transgenic mice) was observed. Pontine nuclei, the affected tissue in transgenic mice, displayed 1.5 times less copies of mtDNA than nonaffected brain tissue hippocampus (odds ratio = 1.21). Pontine nuclei displayed the highest percentage of mtDNA deletions (6.05% more in transgenic mice). Conclusion: These results suggest that mtDNA damage is related to the initiation of the phenotype in transgenic mice; mtDNA 3,867-bp deletions may be a biomarker of the initial stages of the disease.

Keywords:
Mitochondrial DNA, Mitochondrial DNA copy number and deletion, 3,867-bp deletion, Machado-Joseph disease , SCA3, CAG repeats, Ataxin-3, Neurodegenerative disorder, Polyglutamine disorder, Transgenic mouse model
1.
Bettencourt C, Lima M: Machado-Joseph disease: from first descriptions to new perspectives. Orphanet J Rare Dis 2011;6:35.
2.
Schols L, Bauer P, Schmidt T, Schulte T, Riess O: Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis. Lancet Neurol 2004;3:291-304.
3.
Bettencourt C, Fialho RN, Santos C, Montiel R, Bruges-Armas J, Maciel P, Lima M: Segregation distortion of wild-type alleles at the Machado-Joseph disease locus: a study in normal families from the Azores islands (Portugal). J Hum Genet 2008;53:333-339.
4.
Carvalho DR, La Rocque-Ferreira A, Rizzo IM, Imamura EU, Speck-Martins CE: Homozygosity enhances severity in spinocerebellar ataxia type 3. Pediatr Neurol 2008;38:296-299.
5.
Coutinho P: Doença de Machado-Joseph: tentativa de definição; diss., Porto, 1992.
6.
Ichikawa Y, Goto J, Hattori M, Toyoda A, Ishii K, Jeong SY, Hashida H, Masuda N, Ogata K, Kasai F, Hirai M, Maciel P, Rouleau GA, Sakaki Y, Kanazawa I: The genomic structure and expression of MJD, the Machado-Joseph disease gene. J Hum Genet 2001;46:413-422.
7.
Kawaguchi Y, Okamoto T, Taniwaki M, Aizawa M, Inoue M, Katayama S, Kawakami H, Nakamura S, Nishimura M, Akiguchi I, Kimura J, Narumiya S, Kakizuka A: CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nature Genet 1994;8:221-228.
8.
Maciel P, Costa MC, Ferro A, Rousseau M, Santos CS, Gaspar C, Barros J, Rouleau GA, Coutinho P, Sequeiros J: Improvement in the molecular diagnosis of Machado-Joseph disease. Arch Neurol 2001;58:1821-1827.
9.
Maciel P, Gaspar C, DeStefano AL, Silveira I, Coutinho P, Radvany J, Dawson DM, Sudarsky L, Guimarães J, Loureiro JE, Nezarati MM, Corwin LI, Lopes-Cendes I, Rooke K, Rosenberg R, MacLeod P, Farrer LA, Sequeiros J, Rouleau GA: Correlation between CAG repeat length and clinical features in Machado-Joseph disease. Am J Hum Genet 1995;57:54-61.
10.
Orr HT, Zoghbi HY: Trinucleotide repeat disorders. Annu Rev Neurosci 2007;30:575-621.
11.
Paulson HL, Perez MK, Trottier Y, Trojanowski JQ, Subramony SH, Das SS, Vig P, Mandel JL, Fischbeck KH, Pittman RN: Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron 1997;19:333-344.
12.
Yamada M, Hayashi S, Tsuji S, Takahashi H: Involvement of the cerebral cortex and autonomic ganglia in Machado-Joseph disease. Acta Neuropathol 2001;101:140-144.
13.
Paulson H: Machado-Joseph disease/spinocerebellar ataxia type 3. Handb Clin Neurol 2011;103:437-449.
14.
Martin LJ: Mitochondrial and cell death mechanisms in neurodegenerative diseases. Pharmaceuticals (Basel) 2010;3:839-915.
15.
Stack EC, Matson,WR, Ferrante RJ: Evidence of oxidant damage in Huntington's disease: translational strategies using antioxidants. Ann NY Acad Sci 2008;1147:79-92.
16.
Liu C, Cheng W, Kuo S, Li JY, Soong BW, Wei YH: Depletion of mitochondrial DNA in leukocytes of patients with poly-Q diseases. J Neurol Sci 2008;264: 18-21.
17.
Yu Y, Kuo C, Cheng W, Liu C, Hsieh M: Decreased antioxidant enzyme activity and increased mitochondrial DNA damage in cellular models of Machado-Joseph disease. J Neurosci Res 2009;87:1884-1891.
18.
Silva-Fernandes A, Costa MdoC, Duarte-Silva S, Oliveira P, Botelho CM, Martins L, Mariz JA, Ferreira T, Ribeiro F, Correia-Neves M, Costa C, Maciel P: Motor uncoordination and neuropathology in a transgenic mouse model of Machado-Joseph disease lacking intranuclear inclusions and ataxin-3 cleavage products. Neurobiol Dis 2010;40:163-176.
19.
Hill T, Lewicki P: Statistics Methods and Applications: A Comprehensive Reference for Science, Industry, and Data Mining. Tulsa, StatSoft, 2006.
20.
Lin MT, Beal MF: Mitochondrial damage and oxidative stress in neurodegenerative diseases. Nature 2006;443: 787-795.
21.
Su S, Jou S, Cheng W, Lin T, Li J, Huang C, Lee Y, Soong B, Liu C: Mitochondrial DNA damage in spinal and bulbar muscular atrophy patients and carriers. Clin Chim Acta 2010;411: 626-630.
22.
Chen T, He J, Shen L, Fang H, Nie H, Jin T, Wei X, Xin Y, Jiang Y, Li H, Chen G, Lu J, Ba Y: The mitochondrial DNA 4,977-bp deletion and its implication in copy number alteration in colorectal cancer. BMC Med Genet 2011;13:12-18.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.